Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics (NASDAQ:SLN), a clinical-stage biotechnology company focused on developing siRNA therapies, has announced its participation in two upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
Morgan Stanley Global Healthcare Conference
Fireside Chat on Tuesday, September 9, 2025 at 5:35 p.m. ET
-
H.C. Wainwright Global Investment Conference
Fireside Chat on Wednesday, September 10, 2025 at 12:00 p.m. ET
The webcasts can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250902137472/en/
Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Source: Silence Therapeutics plc